Travere Therapeutics annual operating cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Travere Therapeutics Operating Cash Flow Growth & History (TVTX)
Travere Therapeutics's operating cash flow was $37.8M for fiscal 2025.
View full Travere Therapeutics company overviewTravere Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $37.8M | $275.3M | — |
| 2024 | 2024-12-31 | −$237.5M | $42.5M | — |
| 2023 | 2023-12-31 | −$280.0M | −$93.7M | — |
| 2022 | 2022-12-31 | −$186.3M | −$171.5M | — |
| 2021 | 2021-12-31 | −$14.8M | $28.0M | — |
| 2020 | 2020-12-31 | −$42.7M | $15.5M | — |
| 2019 | 2019-12-31 | −$58.2M | −$33.3M | — |
| 2018 | 2018-12-31 | −$25.0M | −$32.4M | — |
| 2017 | 2017-12-31 | $7.4M | $10.8M | — |
| 2016 | 2016-12-31 | −$3.4M | −$2.1M | — |
| 2015 | 2015-12-31 | −$1.4M | $44.5M | — |
| 2014 | 2014-12-31 | −$45.9M | −$28.3M | — |
| 2013 | 2013-12-31 | −$17.6M | −$14.9M | — |
| 2012 | 2012-12-31 | −$2.7M | — | — |
| 2011 | 2012-02-29 | −$49 | $640 | — |
| 2010 | 2011-02-28 | −$689 | — | — |
Travere Therapeutics quarterly operating cash flow
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q1.12
Q1.12
Q2.12
Q2.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $58.1M | $53.1M | +1065.38% |
| Q1 2026 | 2026-03-31 | −$40.4M | $1.8M | — |
| Q4 2025 | 2025-12-31 | $60.7M | $96.4M | — |
| Q3 2025 | 2025-09-30 | $14.3M | $56.8M | — |
| Q2 2025 | 2025-06-30 | $5.0M | $45.2M | — |
| Q1 2025 | 2025-03-31 | −$42.2M | $76.8M | — |
| Q4 2024 | 2024-12-31 | −$35.7M | $34.8M | — |
| Q3 2024 | 2024-09-30 | −$42.5M | $16.6M | — |
| Q2 2024 | 2024-06-30 | −$40.2M | $29.1M | — |
| Q1 2024 | 2024-03-31 | −$119.0M | −$37.9M | — |
| Q4 2023 | 2023-12-31 | −$70.5M | −$15.8M | — |
| Q3 2023 | 2023-09-30 | −$59.1M | −$19.6M | — |
| Q2 2023 | 2023-06-30 | −$69.3M | −$32.5M | — |
| Q1 2023 | 2023-03-31 | −$81.1M | −$25.8M | — |
| Q4 2022 | 2022-12-31 | −$54.6M | −$27.8M | — |
| Q3 2022 | 2022-09-30 | −$39.5M | −$71.6M | — |
| Q2 2022 | 2022-06-30 | −$36.8M | −$43.3M | — |
| Q1 2022 | 2022-03-31 | −$55.3M | −$28.8M | — |
| Q4 2021 | 2021-12-31 | −$26.9M | −$13.0M | — |
| Q3 2021 | 2021-09-30 | $32.1M | $25.3M | +376.07% |
| Q2 2021 | 2021-06-30 | $6.5M | $12.9M | — |
| Q1 2021 | 2021-03-31 | −$26.5M | $2.7M | — |
| Q4 2020 | 2020-12-31 | −$13.9M | −$9.4M | — |
| Q3 2020 | 2020-09-30 | $6.7M | $20.9M | — |
| Q2 2020 | 2020-06-30 | −$6.5M | $12.7M | — |
| Q1 2020 | 2020-03-31 | −$29.2M | −$8.7M | — |
| Q4 2019 | 2019-12-31 | −$4.5M | −$927,000 | — |
| Q3 2019 | 2019-09-30 | −$14.1M | −$10.2M | — |
| Q2 2019 | 2019-06-30 | −$19.1M | −$16.3M | — |
| Q1 2019 | 2019-03-31 | −$20.5M | −$5.8M | — |
| Q4 2018 | 2018-12-31 | −$3.6M | −$2.2M | — |
| Q3 2018 | 2018-09-30 | −$3.9M | −$10.1M | — |
| Q2 2018 | 2018-06-30 | −$2.8M | −$8.8M | — |
| Q1 2018 | 2018-03-31 | −$14.7M | −$11.3M | — |
| Q4 2017 | 2017-12-31 | −$1.4M | $7.1M | — |
| Q3 2017 | 2017-09-30 | $6.2M | $1.6M | +33.90% |
| Q2 2017 | 2017-06-30 | $6.0M | $2.0M | +51.00% |
| Q1 2017 | 2017-03-31 | −$3.4M | $160,000 | — |
| Q4 2016 | 2016-12-31 | −$8.5M | −$4.9M | — |
| Q3 2016 | 2016-09-30 | $4.6M | $3.9M | +526.39% |
| Q2 2016 | 2016-06-30 | $4.0M | −$4.0M | −50.24% |
| Q1 2016 | 2016-03-31 | −$3.6M | $3.0M | — |
| Q4 2015 | 2015-12-31 | −$3.6M | $5.5M | — |
| Q3 2015 | 2015-09-30 | $739,000 | $16.2M | — |
| Q2 2015 | 2015-06-30 | $8.0M | $19.5M | — |
| Q1 2015 | 2015-03-31 | −$6.6M | $3.2M | — |
| Q4 2014 | 2014-12-31 | −$9.1M | −$697,886 | — |
| Q3 2014 | 2014-09-30 | −$15.5M | −$13.1M | — |
| Q2 2014 | 2014-06-30 | −$11.4M | −$9.2M | — |
| Q1 2014 | 2014-03-31 | −$9.8M | −$5.2M | — |
| Q4 2013 | 2013-12-31 | −$8.4M | — | — |
| Q3 2013 | 2013-09-30 | −$2.4M | −$1.9M | — |
| Q2 2013 | 2013-06-30 | −$2.2M | −$1.8M | — |
| Q1 2013 | 2013-03-31 | −$4.6M | −$3.4M | — |
| Q2 2012 · Sep 30 | 2012-09-30 | −$471,256 | — | — |
| Q2 2012 · Aug 31 | 2012-08-31 | $0 | $25 | — |
| Q1 2012 · Jun 30 | 2012-06-30 | −$394,969 | — | — |
| Q1 2012 · May 31 | 2012-05-31 | −$9 | $15 | — |
| Q1 2012 · Mar 31 | 2012-03-31 | −$1.2M | — | — |
| Q4 2011 | 2012-02-29 | $18 | — | — |
| Q3 2011 | 2011-11-30 | −$18 | $73 | — |
| Q2 2011 | 2011-08-31 | −$25 | — | — |
| Q1 2011 | 2011-05-31 | −$24 | — | — |
| Q3 2010 | 2010-11-30 | −$91 | — | — |
Travere Therapeutics operating cash flow trends
Over the last five fiscal years, Travere Therapeutics's operating cash flow increased from −$42.7M to $37.8M, a change of $80.5M. The latest reported quarter, Q2 2026, shows $58.1M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Travere Therapeutics source filings ↗